 |
|
Evidence-Based Dermatology
Edited by Hywel Williams, Michael Bigby, Thomas Diepgen, Andrew Herxheimer, Luigi Naldi, and Berthold Rzany
2nd ed, 723 pp, $300.25
Malden, MA, Blackwell Publishing, 2008
ISBN-13: 978-1-4051-4518-3
JAMA. 2009;301(11):1179-1180.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
This hefty tome, now in its second edition, starts with 14 chapters on the basis and meaning of evidence-based medicine and dermatology. These chapters have titles such as "The Field and Its Boundaries," "The Rationale for Evidence-based Dermatology," "The Cochrane Skin Group," "Critical Appraisal of Pharmacoeconomic Studies," and, most significantly, "How to Critically Appraise a Randomized Controlled Trial." The chapters are clear and well written, with informative tables and line drawings printed in color. The text includes many pearls and useful data. References are pertinent and up to date. Unfortunately, the writing does have a whiff of defensiveness. As an example, the preface by Williams starts by saying that "Evidence-based dermatology is no longer a dirty word in dermatology." A more serene approach might have been more desirable.
Chapters 15 to 57 comprise the bulk of the book (approximately 600 pages) and cover a variety of clinical subjects, from acne . . . [Full Text of this Article]
Lawrence C. Parish, MD, Reviewer
Department of Dermatology
Jefferson Medical College of Thomas Jefferson University
Philadelphia, Pennsylvania
larryderm@yahoo.com
Mauricio Goihman-Yahr, MD, Reviewer
Vargas School of Medicine
Central University of Venezuela
Caracas
mgoihmanyahr@yahoo.com
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
